Development	development	O	O	O	O
of	of	O	O	O	O
levodopa-induced	levodopa-induced	O	O	O	O
dyskinesias	dyskinesias	O	DISEASE	OTHERS	I
in	in	O	O	O	O
parkinsonian	parkinsonian	O	DISEASE	OTHERS	I
monkeys	monkeys	O	O	O	O
may	may	O	O	O	O
depend	depend	O	O	O	O
upon	upon	O	O	O	O
rate	rate	O	O	O	O
of	of	O	O	O	O
symptom	symptom	O	O	O	O
onset	onset	O	O	O	O
and/or	and/or	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
symptoms	symptoms	O	O	O	O
.	.	O	O	O	O

Levodopa-induced	levodopa-induced	O	O	O	O
dyskinesias	dyskinesias	O	DISEASE	OTHERS	I
(	(	O	O	O	O
LIDs	lids	O	DISEASE	OTHERS	I
)	)	O	O	O	O
present	present	O	O	O	O
a	a	O	O	O	O
major	major	O	O	O	O
problem	problem	O	O	O	O
for	for	O	O	O	O
the	the	O	O	O	O
long-term	long-term	O	O	O	O
management	management	O	O	O	O
of	of	O	O	O	O
Parkinson	parkinson	O	DISEASE	OTHERS	I
's	's	O	DISEASE	OTHERS	I
disease	disease	O	DISEASE	OTHERS	I
(	(	O	O	O	O
PD	pd	O	DISEASE	OTHERS	I
)	)	O	O	O	O
patients	patients	O	O	O	O
.	.	O	O	O	O

Due	due	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
interdependence	interdependence	O	O	O	O
of	of	O	O	O	O
risk	risk	O	O	O	O
factors	factors	O	O	O	O
in	in	O	O	O	O
clinical	clinical	O	O	O	O
populations	populations	O	O	O	O
,	,	O	O	O	O
it	it	O	O	O	O
is	is	O	O	O	O
difficult	difficult	O	O	O	O
to	to	O	O	O	O
independently	independently	O	O	O	O
examine	examine	O	O	O	O
factors	factors	O	O	O	O
that	that	O	O	O	O
may	may	O	O	O	O
influence	influence	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
LIDs	lids	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Using	using	O	O	O	O
macaque	macaque	O	O	O	O
monkeys	monkeys	O	O	O	O
with	with	O	O	O	O
different	different	O	O	O	O
types	types	O	O	O	O
of	of	O	O	O	O
MPTP-induced	mptp-induced	O	O	O	O
parkinsonism	parkinsonism	O	DISEASE	OTHERS	I
,	,	O	O	O	O
the	the	O	O	O	O
current	current	O	O	O	O
study	study	O	O	O	O
evaluated	evaluated	O	O	O	O
the	the	O	O	O	O
degree	degree	O	O	O	O
to	to	O	O	O	O
which	which	O	O	O	O
rate	rate	O	O	O	O
of	of	O	O	O	O
symptom	symptom	O	O	O	O
progression	progression	O	O	O	O
,	,	O	O	O	O
symptom	symptom	O	O	O	O
severity	severity	O	O	O	O
,	,	O	O	O	O
and	and	O	O	O	O
response	response	O	O	O	O
to	to	O	O	O	O
and	and	O	O	O	O
duration	duration	O	O	O	O
of	of	O	O	O	O
levodopa	levodopa	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
may	may	O	O	O	O
be	be	O	O	O	O
involved	involved	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
LIDs	lids	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Monkeys	monkeys	O	O	O	O
with	with	O	O	O	O
acute	acute	O	O	O	O
(	(	O	O	O	O
short-term	short-term	O	O	O	O
)	)	O	O	O	O
MPTP	mptp	CHEMICALS	O	OTHERS	I
exposure	exposure	O	O	O	O
,	,	O	O	O	O
rapid	rapid	O	O	O	O
symptom	symptom	O	O	O	O
onset	onset	O	O	O	O
and	and	O	O	O	O
short	short	O	O	O	O
symptom	symptom	O	O	O	O
duration	duration	O	O	O	O
prior	prior	O	O	O	O
to	to	O	O	O	O
initiation	initiation	O	O	O	O
of	of	O	O	O	O
levodopa	levodopa	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
developed	developed	O	O	O	O
dyskinesia	dyskinesia	O	DISEASE	OTHERS	I
between	between	O	O	O	O
11	11	O	O	O	O
and	and	O	O	O	O
24	24	O	O	O	O
days	days	O	O	O	O
of	of	O	O	O	O
daily	daily	O	O	O	O
levodopa	levodopa	CHEMICALS	O	OTHERS	I
administration	administration	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
contrast	contrast	O	O	OTHERS	I
,	,	O	O	O	O
monkeys	monkeys	O	O	O	O
with	with	O	O	O	O
long-term	long-term	O	O	O	O
MPTP	mptp	CHEMICALS	O	OTHERS	I
exposure	exposure	O	O	O	O
,	,	O	O	O	O
slow	slow	O	O	O	O
symptom	symptom	O	O	O	O
progression	progression	O	O	O	O
and/or	and/or	O	O	O	O
long	long	O	O	O	O
symptom	symptom	O	O	O	O
duration	duration	O	O	O	O
prior	prior	O	O	O	O
to	to	O	O	O	O
initiation	initiation	O	O	O	O
of	of	O	O	O	O
levodopa	levodopa	CHEMICALS	O	OTHERS	I
therapy	therapy	O	O	O	O
were	were	O	O	O	O
more	more	O	O	O	O
resistant	resistant	O	O	O	O
to	to	O	O	O	O
developing	developing	O	O	O	O
LIDs	lids	O	DISEASE	OTHERS	I
(	(	O	O	O	O
e.g.	e.g.	O	O	O	O
,	,	O	O	O	O
dyskinesia	dyskinesia	O	DISEASE	OTHERS	I
developed	developed	O	O	O	O
no	no	O	O	O	O
sooner	sooner	O	O	O	O
than	than	O	O	O	O
146	146	O	O	O	O
days	days	O	O	O	O
of	of	O	O	O	O
chronic	chronic	O	O	O	O
levodopa	levodopa	CHEMICALS	O	OTHERS	I
administration	administration	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

All	all	O	O	O	O
animals	animals	O	O	O	O
were	were	O	O	O	O
similarly	similarly	O	O	O	O
symptomatic	symptomatic	O	O	O	O
at	at	O	O	O	O
the	the	O	O	O	O
start	start	O	O	O	O
of	of	O	O	O	O
levodopa	levodopa	CHEMICALS	O	OTHERS	I
treatment	treatment	O	O	O	O
and	and	O	O	O	O
had	had	O	O	O	O
similar	similar	O	O	O	O
therapeutic	therapeutic	O	O	O	O
responses	responses	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
data	data	O	O	O	O
suggest	suggest	O	O	O	O
distinct	distinct	O	O	O	O
differences	differences	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
propensity	propensity	O	O	O	O
to	to	O	O	O	O
develop	develop	O	O	O	O
LIDs	lids	O	DISEASE	OTHERS	I
in	in	O	O	O	O
monkeys	monkeys	O	O	O	O
with	with	O	O	O	O
different	different	O	O	O	O
rates	rates	O	O	O	O
of	of	O	O	O	O
symptom	symptom	O	O	O	O
progression	progression	O	O	O	O
or	or	O	O	O	O
symptom	symptom	O	O	O	O
durations	durations	O	O	O	O
prior	prior	O	O	O	O
to	to	O	O	O	O
levodopa	levodopa	CHEMICALS	O	OTHERS	I
and	and	O	O	O	O
demonstrate	demonstrate	O	O	O	O
the	the	O	O	O	O
value	value	O	O	O	O
of	of	O	O	O	O
these	these	O	O	O	O
models	models	O	O	O	O
for	for	O	O	O	O
further	further	O	O	O	O
studying	studying	O	O	O	O
the	the	O	O	O	O
pathophysiology	pathophysiology	O	O	O	O
of	of	O	O	O	O
LIDs	lids	O	DISEASE	OTHERS	I
.	.	O	O	O	O

